Revolymer chews over market approval

Nicotine gum manufacturer Revolymer, a spin-out of Bristol University, has filed for market authorisation in Europe to sell its primary products with the Medicines and Healthcare products Regulatory Agency (MHRA).

If approved, the company will begin marketing its 2mg and 4mg strength gum in the UK, Ireland, Poland, and Spain.

The company, which also makes other polymer based consumer products and is backed by commercialisation firm the IP Group and commercialisation partnership SETsquared, was founded in 2005. Since then, it has gone on to raise £18.55m ($30m) in venture backing and a further £1m in grants. In 2012, the company held its initial public offering on London’s Alternative Investment Market, during which it raised a further £25m.

Roger Pettman, chief executive of Revolymer, said: “I am pleased that our strategy to commercialise our nicotine gum products in Europe is progressing, as demonstrated by the achievement of this latest milestone. We believe that not only is our product bioequivalent to the existing reference product in Europe, but that it has additional benefits that consumers will value, namely a more confectionery-like chew.”